These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 9816102

  • 1. p53 protein in non-small cell lung cancer as quantitated by enzyme-linked immunosorbent assay: relation to prognosis.
    Pappot H, Francis D, Brünner N, Grondahl-Hansen J, Osterlind K.
    Clin Cancer Res; 1996 Jan; 2(1):155-60. PubMed ID: 9816102
    [Abstract] [Full Text] [Related]

  • 2. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
    Pedersen H, Brünner N, Francis D, Osterlind K, Rønne E, Hansen HH, Danø K, Grøndahl-Hansen J.
    Cancer Res; 1994 Sep 01; 54(17):4671-5. PubMed ID: 8062262
    [Abstract] [Full Text] [Related]

  • 3. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
    Hirai K, Koizumi K, Haraguchi S, Hirata T, Mikami I, Fukushima M, Yamagishi S, Kawashima T, Okada D, Shimizu K, Kawamoto M.
    Ann Thorac Surg; 2005 Jan 01; 79(1):248-53. PubMed ID: 15620951
    [Abstract] [Full Text] [Related]

  • 4. Altered retinoblastoma and p53 protein status in non-small cell carcinoma of the lung: potential synergistic effects on prognosis.
    Xu HJ, Cagle PT, Hu SX, Li J, Benedict WF.
    Clin Cancer Res; 1996 Jul 01; 2(7):1169-76. PubMed ID: 9816284
    [Abstract] [Full Text] [Related]

  • 5. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer.
    Werle B, Kotzsch M, Lah TT, Kos J, Gabrijelcic-Geiger D, Spiess E, Schirren J, Ebert W, Fiehn W, Luther T, Magdolen V, Schmitt M, Harbeck N.
    Anticancer Res; 2004 Jul 01; 24(6):4147-61. PubMed ID: 15736466
    [Abstract] [Full Text] [Related]

  • 6. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.
    Oyama T, Osaki T, Nose N, Ichiki Y, Inoue M, Imoto H, Yoshimatsu T, Kodate M, Uramoto H, Mizoue T, Yano K, Yasumoto K.
    Anticancer Res; 2000 Jul 01; 20(1B):505-10. PubMed ID: 10769714
    [Abstract] [Full Text] [Related]

  • 7. Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer.
    Bozcuk H, Gumus A, Ozbilim G, Sarper A, Kucukosmanoglu I, Ozbudak IH, Artac M, Ozdogan M, Samur M, Kaya A, Savas B.
    Med Sci Monit; 2005 Jun 01; 11(6):HY11-20. PubMed ID: 15917726
    [Abstract] [Full Text] [Related]

  • 8. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
    Offersen BV, Pfeiffer P, Andreasen P, Overgaard J.
    Lung Cancer; 2007 Apr 01; 56(1):43-50. PubMed ID: 17207889
    [Abstract] [Full Text] [Related]

  • 9. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma.
    Pedersen H, Grøndahl-Hansen J, Francis D, Osterlind K, Hansen HH, Danø K, Brünner N.
    Cancer Res; 1994 Jan 01; 54(1):120-3. PubMed ID: 8261432
    [Abstract] [Full Text] [Related]

  • 10. Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer.
    Pavey SJ, Marsh NA, Ray MJ, Butler D, Dare AJ, Hawson GA.
    Boll Soc Ital Biol Sper; 1996 Jan 01; 72(11-12):331-40. PubMed ID: 9178585
    [Abstract] [Full Text] [Related]

  • 11. The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis.
    Pappot H, Pedersen AN, Brünner N, Christensen IJ.
    Lung Cancer; 2006 Feb 01; 51(2):193-200. PubMed ID: 16325301
    [Abstract] [Full Text] [Related]

  • 12. Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung carcinomas.
    Mørkve O, Halvorsen OJ, Skjaerven R, Stangeland L, Gulsvik A, Laerum OD.
    Anticancer Res; 1993 Feb 01; 13(3):571-8. PubMed ID: 8391242
    [Abstract] [Full Text] [Related]

  • 13. Prognostic significance of expression of p53 oncoprotein in primary (stage I-IIIa) non-small cell lung cancer.
    Tan DF, Li Q, Rammath N, Beck A, Wiseman S, Anderson T, al-Salameh A, Brooks J, Bepler G.
    Anticancer Res; 2003 Feb 01; 23(2C):1665-72. PubMed ID: 12820438
    [Abstract] [Full Text] [Related]

  • 14. The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival.
    Bergqvist M, Brattström D, Larsson A, Hesselius P, Brodin O, Wagenius G.
    BMC Cancer; 2004 Sep 14; 4():66. PubMed ID: 15367333
    [Abstract] [Full Text] [Related]

  • 15. Lack of association between level of Plasminogen Activator Inhibitor-1 and estimates of tumor angiogenesis in early breast cancer.
    Offersen BV, Riisbro R, Knoop A, Brünner N, Overgaard J, Danish Breast Cancer Cooperative Group (DBCG) Tumor Biology Committee.
    Acta Oncol; 2007 Sep 14; 46(6):782-91. PubMed ID: 17653901
    [Abstract] [Full Text] [Related]

  • 16. Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma.
    Törmänen U, Eerola AK, Rainio P, Vähäkangas K, Soini Y, Sormunen R, Bloigu R, Lehto VP, Pääkkö P.
    Cancer Res; 1995 Dec 01; 55(23):5595-602. PubMed ID: 7585640
    [Abstract] [Full Text] [Related]

  • 17. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
    Mohamed S, Yasufuku K, Hiroshima K, Nakajima T, Yoshida S, Suzuki M, Sekine Y, Shibuya K, Iizasa T, Farouk A, Fujisawa T.
    Cancer; 2007 Jun 15; 109(12):2506-14. PubMed ID: 17487846
    [Abstract] [Full Text] [Related]

  • 18. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L, Orre LM, Kanter L, Pernemalm M, Koyi H, Lewensohn R, Lehtiö J.
    Lung Cancer; 2009 Mar 15; 63(3):410-7. PubMed ID: 18620780
    [Abstract] [Full Text] [Related]

  • 19. bcl-2 and p53 protein expression in non-small cell lung cancers: correlation with survival time.
    Ohsaki Y, Toyoshima E, Fujiuchi S, Matsui H, Hirata S, Miyokawa N, Kubo Y, Kikuchi K.
    Clin Cancer Res; 1996 May 15; 2(5):915-20. PubMed ID: 9816250
    [Abstract] [Full Text] [Related]

  • 20. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer.
    Ebina M, Steinberg SM, Mulshine JL, Linnoila RI.
    Cancer Res; 1994 May 01; 54(9):2496-503. PubMed ID: 7909277
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.